Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sven Breitschwerdt has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Paucisymptomatic opisthorchiasis in a non-endemic country: a neglected differential diagnosis?

    by S. Dirik, C. Boesecke, S. Breitschwerdt, S. M. Fünger, A. Hoerauf, M. P. Hübner, G. J. Rieke, J. K. Rockstroh, J. C. Wasmuth, H. Wobser, et al.

    Case presentation: We report a case of opisthorchiasis in a 71-year-old woman with intermittent upper abdominal pain, whose cause had remained unclear for a long time. She grew up in Kazakhstan and moved to Germany more than 30 years ago. After positive serological testing for Opisthorchis during a recent visit to her home country, she presented at our clinic for further evaluation. Stool examination confirmed the presence of Opisthorchis eggs. The symptoms quickly resolved after treatment with praziquantel. Abdominal sonography revealed adenomyomatosis of the gallbladder fundus and multiple gallbladder polyps, most likely a consequence of chronic inflammation caused by the parasite. Sonographic surveillance was recommended with regard to a potentially increased risk of cholangiocarcinoma. Discussion and conclusions: No certified serological test for opisthorchiasis is available in Germany and molecular or antigen-based tests for this infection are also largely unavailable. Diagnosis therefore has to rely on stool microscopy which requires the examination of multiple samples to ensure adequate sensitivity. Diagnosis is further complicated as symptoms are often nonspecific and liver flukes are usually not among the initial differential diagnoses. Missing the diagnosis, however, carries the risk of serious complications. Global travel and migration as well as recent autochthonous cases in the European Union underscore the need for increased vigilance for opisthorchiasis even in non-endemic areas.

  • Open Access

    Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?

    by Arda Kaya, Dominik Benke, Tracy Swan, Sven Breitschwerdt, Jan‐Christian Wasmuth, Christoph Boesecke, Jürgen Kurt Rockstroh


  • Open Access

    Consensus Sequences for Gag and Pol Introduced into HIV-1 Clade B Laboratory Strains Differentially Influence the Impact of Point Mutations Associated with Immune Escape and with Drug Resistance on Viral Replicative Capacity

    by Sven Breitschwerdt, Benedikt Grandel, Benedikt Asbach, Franziska Winter, Todd Allen, Ralf Wagner, Bernd Salzberger, Arne Schneidewind

    Viral evasion from effective human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses and from antiretroviral therapy through viral sequence variation is frequently accompanied by a loss in viral fitness. The impact of sequence variations on replication capacity in vitro was mostly studied by introducing single mutations into a specific clonal strain such as NL4-3. How the specific viral backbone itself impacts replicative fitness remains elusive. To test for a potential effect of the viral backbone, we constructed HIV-1 clade B clones with consensus sequences for gag and/or pol and evaluated the infectivity of viral variants harboring well-defined cytotoxic T-lymphocyte (CTL) escape mutations or drug resistance mutations within this backbone or the clonal NL4-3 strain. Viral variants with consensus sequences were replication-competent in vitro, although at lower rates than the NL4-3 virus. Introduction of the dominant CTL escape mutation R264K into the newly constructed viruses or into NL4-3 led to a dramatic reduction in infection rates. In contrast to the NL4-3 backbone, the combination of R264K with its compensatory mutation S173A on the consensus backbone led to higher infection rates as compared to the same virus in the absence of R264K and S173A. Furthermore, 2 out of 10 drug resistance mutations in pol led to opposing effects, with an increase in infection rates on the consensus gag/pol backbone and a reduction on NL4-3. Therefore, the effect of the respective viral backbone on infectivity observed in vitro might constitute an additional factor to explain differential kinetics of mutational evasion from immune and pharmaceutical pressure.

  • Open Access

    HIV Care in Ukrainian Migrants in Two European Countries: All the Same?

    by Kathrin van Bremen, Miłosz Parczewski, Malte Monin, Magdalena Leszczyszyn-Pynka, Stefan Schlabe, Franciszek Lenkiewicz, Malwina Karasińska-Cieślak, Jan-Christian Wasmuth, Magdalena Witak-Jędra, Sven Breitschwerdt, et al.

    Introduction: War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two infectious disease departments in Bonn, Germany, and Szczecin, Poland. Methods: This is a retrospective study on 161 people living with HIV (PLWH) refugees from Ukraine seeking care in Bonn (n = 30) and Szczecin (n = 131) between April 2022 and May 2023. Demographic, virologic, immunologic, and coinfection data were analyzed. Results: The majority of the studied individuals were female: 64% (n = 84) in Szczecin and 60% (n = 18) in Bonn. The main HIV transmission mode was heterosexual sex in 73.5% (n = 114). All were on combined antiretroviral therapy (cART) on arrival, primarily on the TLD regimen (TDF/3TC/DTG) (68.4%, n = 106). In Germany, cART was most frequently switched to BIC/TAF/FTC in 83.4% (n = 25); in Poland, the most common combination was TDF/FTC + DTG (58%, n = 76). A prevalence of replicating hepatitis C was in 11.7% (n = 15), and that for chronic hepatitis B (HBV) was in 4.7% (n = 4). History of past tuberculosis was reported in 16.9% (n = 14, Poland, and n = 7, Germany). Follow-up after 6 months showed immunological reconstitution with a mean increase of CD4+ of 10 (IQR: −69.5–120.5) cells/µL in Poland and 51.5 (IQR: −22.5–135.5) cells/µL in Germany; p = 0.04. Virologic suppression (<40 HIV-RNA/mL) was high in care entry (n = 62; 98%) for Poland, and n = 26 (92.6%) for Germany, and suppression was achieved in the majority of patients in the 6-month control (89.7% in Poland vs. 95.7% in Germany). Conclusions: Health challenges posed by war migration extend beyond HIV to coinfections as HBV, HCV, and tuberculosis give an indication for a broader search for coinfections, often less common in the new country.


  • Open Access

    Hepatitis delta in HIV/hepatitis B coinfection: A call for action

    by Didem Celik, Kathrin van Bremen, Sven Breitschwerdt, Fauzi Elamouri, Tracy Swan, Christoph Boesecke, Jürgen K. Rockstroh, Patrick Ingiliz


  • Open Access

    Implementation of EACS vaccination recommendations among people living with HIV

    by Sven Breitschwerdt, Carolynne Schwarze-Zander, Ahmad Al Tayy, Julia Mutevelli, Jan-Christian Wasmuth, Jürgen K. Rockstroh, Christoph Boesecke

    Objectives: With modern combination antiretroviral Treatment (cART) a normal life expectancy among people living with HIV (PLWH) has become reality if started early enough prior to the onset of more pronounced immunodeficiency. Therefore, prevention measures against other infectious diseases among this vulnerable group have gained increased attention. Indeed, the EACS guidelines recommend vaccinations against HAV, HBV, HPV, Influenza, Neisseria meningitidis, Streptococcus pneumoniae and VZV in HIV-infected adults. Methods: All PLWH under cART attending our ID outpatient clinic between April to June 2018, were assessed during consultation for vaccination status regarding pneumococcus, Hepatitis A and B, influenza, varicella, meningococcus and HPV using a pre-defined questionnaire, vaccination certificates and medical records. In addition, the cohort database was screened for Hepatitis A and B serology and HIV surrogate markers. Results: A total of 305 PLWH (82.3% male, 17.7% female) was included, median age was 48 years (IQR 47–51). Median CD4 + T cell count was 543 (IQR 304–770), and for 297 (97.4%) PLWH CD4 + T cell count was ≥ 200/ul. The viral load was undetectable (< 40 copies/ml) in 289 (94.8%) cases. Highest vaccination rates were observed for HAV (87.4%), Streptococcus pneumoniae (77.4%) and Influenza (76.5%). 64.3% PLWH got vaccinated against HBV, whereas VZV vaccination only played a minor role, in the context of the high rate of cleared infections (99.0%). Lowest vaccination rates were detected for HPV (0%) and Neisseria meningitidis (3.0%). Conclusions: Our data suggest that vaccination rates among PLWH are higher compared to the general German population. Implementation of EACS guidelines into daily routine though is not fully executed and the need for improving vaccination rates has to be emphasized. Centrally organized vaccination registers as well as electronic medical records could be helpful tools to detect a lack of vaccination coverage and send digital vaccination reminders particularly among risk groups.


  • Open Access

    Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection

    by Kathrin van Bremen, Christian Hoffmann, Stefan Mauss, Thomas Lutz, Patrick Ingiliz, Christoph D. Spinner, Stefan Scholten, Carolynne Schwarze‐Zander, Florian Berger, Sven Breitschwerdt, et al.

    Several cohorts have shown that long‐term tenofovir‐containing combination antiretroviral therapy (cART) leads to higher HBsAg seroclearance rates in HIV/HBV coinfected patients vs HBV‐monoinfected patients under tenofovir disoproxil fumarate (TDF)‐based therapy. We have analysed data on determinants of HBsAg loss in a retrospective multicentric cohort of 359 HIV/HBV coinfected patients. Median CD4 T‐cell count at baseline was 359/ul (321‐404), CDC stage was C in 20% (n = 70). Most patients (68%) were ART‐naïve when TDF‐ or tenofovir alafenamide (TAF)‐containing cART was initiated (baseline). After a median follow‐up of 11 years HBsAg loss had occurred in 66/359 (18%) patients. However, patients with stage CDC C (P ≤ .001), lower CD4 gain (P = .043) and not receiving TDF/FTC (P = .008) were less likely to lose HBsAg. Long‐term TDF‐containing cART appears to achieve higher rates of HBsAg seroclearance compared to published data for HBV monoinfected subjects. However, late presentation for HIV and poor immune recovery significantly impair HBV seroconversion rates.